Huan Wang^1,#, Jindong Xie^1,#, Na Li¹, Qianwen Liu¹, Wenqi Song¹, Wenkuan Chen¹, Cheng Peng^2,*, Hailin Tang^1,*

Oncology Research, Vol.33, No.12, pp. 3789-3800, 2025, DOI:10.32604/or.2025.067592 - 27 November 2025

Abstract Solid tumors comprise the majority of the global cancer burden, with their incidence and associated mortality posing considerable challenges to public health systems. With population growth and aging, the burden of these tumors is anticipated to increase further in the coming decades. The progression of solid tumors depends on dynamic interactions between malignantly transformed cells and the tumor microenvironment (TME). Immune checkpoint inhibitor therapy improves T cell-mediated antitumor activity by suppressing regulatory pathways, such as programmed cell death protein 1/programmed death-ligand 1. Nonetheless, its widespread application is constrained by drug resistance. In this comprehensive review, More >

Madeline Keane¹, Natalia Wojciechowska², Lindsay Zumwalt^1,*, Emilie Sandfeld³, Alejandra Dominguez¹, Jason Wang², Anish Ray²

Oncology Research, Vol.33, No.8, pp. 1895-1908, 2025, DOI:10.32604/or.2025.065547 - 18 July 2025

Abstract Background: Precision medicine is an emerging approach for treating pediatric cancer due to its ability to target tumor-specific genetic drivers rather than provide broad and aggressive treatments. The study aimed to outline the establishment and impact of a Precision Medicine Clinic (PMC) in the setting of pediatric oncology, with the objective of offering targeted treatment options within the institution and creating a scalable model for adoption by other healthcare systems to achieve a wider impact. Methods: Recognizing this need for an individualized approach to treating patients, Cook Children’s Medical Center (CCMC) established a multidisciplinary molecular… More >

Dongqing Wang^1,*, Heying Chen¹, Yi Hu^2,*

Oncologie, Vol.24, No.3, pp. 441-449, 2022, DOI:10.32604/oncologie.2022.024898 - 19 September 2022

Abstract Immunotherapy is currently recognized as one of the most promising anticancer strategies. In the tumor microenvironment, tumor-associated macrophages are mainly M2-type macrophages with tumor-promoting effects. Therefore, the reprogramming of tumor-associated macrophages from M2 to M1 type is a potential strategy for cancer therapy. We have previously shown the anticancer effects of implantable allogeneic M1 macrophages in mice. Here, we further engineered autologous mouse bone marrow cells into M1 macrophages and then embedded them into a sodium alginate gel to prepare an implantable immunotherapeutic agent (M1@Gel). We demonstrate that M1@Gel repolarizes M2 macrophages to M1 type More >

FRANCESCO MAININI^*

BIOCELL, Vol.45, No.5, pp. 1171-1173, 2021, DOI:10.32604/biocell.2021.017399 - 12 July 2021

Abstract Adoptive cell therapy and Immune Checkpoint Blockade Inhibitors have recently revolutionized the field of oncology. However, these types of immunotherapeutic approaches have limited success in treating solid tumors. In particular, chimeric antigen receptor (CAR)-T cells efficacy is hampered by immunosuppressive signals in the tumor microenvironment (TME) and by a limited infiltration of re-infused T cells to the tumor site. The field of nanobiotechnology applied to oncology is also rapidly expanding. Nanoparticles-based delivery systems can be employed to modulate the activity of immune cells present in the TME enhancing the efficacy of CAR-T cells. Interestingly, nano-backpacks More >